Clinical Report: Evaluating the Efficacy and Safety of Preventive Therapies for Vestibular Migraine
Overview
This systematic review and network meta-analysis evaluated the efficacy and safety of various preventive therapies for vestibular migraine (VM). Findings indicate that all medications significantly reduced vertigo attacks, with propranolol showing the largest benefits, while the CGRP antibody galcanezumab demonstrated the strongest evidence quality and tolerability.
Background
Vestibular migraine affects 1–3% of the population and is a leading cause of recurrent vertigo, significantly impairing quality of life. Current treatment options are largely empirical, lacking specific evidence for VM, which complicates clinical decision-making. The economic burden of VM is substantial, highlighting the need for effective preventive therapies.
Data Highlights
No specific numerical data was provided in the source material.
Key Findings
All preventive medications analyzed significantly reduced vertigo attacks.
Propranolol showed the largest benefits among traditional migraine preventives.
Galcanezumab, a newer CGRP antibody, had the strongest evidence quality and best tolerability.
The analysis emphasizes the need for direct comparison studies between promising treatments.
Current treatment approaches for VM are largely empirical, borrowing from migraine prophylaxis.
Clinical Implications
Clinicians should consider the comparative effectiveness and tolerability of preventive treatments for vestibular migraine when making treatment decisions. The findings support the use of propranolol and galcanezumab as viable options, while highlighting the need for further studies to establish clearer treatment guidelines.
Conclusion
This systematic review provides valuable insights into the efficacy and safety of preventive therapies for vestibular migraine, aiding clinicians in treatment selection. Future research should focus on direct comparisons of the most promising therapies to enhance clinical guidance.
